NeuroMab™ Anti-CD284 Antibody(NRP-0422-P743)

Figure 1 is a graph depicting the binding of a murine monoclonal antibody (referred to herein as "16G7") to the TLR4/MD-2 complex.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 2 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production in TLR4/MD-2 transfected HEK 293 cells by monoclonal antibody mu16G7.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 3 depicts the inhibition of LPS-induced IL-8 production in human whole blood by monoclonal antibody mu16G7.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 4 is a series of graphs depicting the specificity of mu16G7 monoclonal antibody for TLR4.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.